The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Open accessAbstract
RationaleThis dose-effect study extends previous observations showing that psilocybin can occasion mystical-type experiences having persisting positive effects on attitudes, mood, and behavior.ObjectivesThis double-blind study evaluated psilocybin (0, 5, 10, 20, 30 mg/70 kg, p.o.) administered under supportive conditions.MethodsParticipants were 18 adults (17 hallucinogen-naïve). Five 8-h sessions were conducted individually for each participant at 1-month intervals. Participants were randomized to receive the four active doses in either ascending or descending order (nine participants each). Placebo was scheduled quasi-randomly. During sessions, volunteers used eyeshades and were instructed to direct their attention inward. Volunteers completed questionnaires assessing effects immediately after and 1 month after each session, and at 14 months follow-up.ResultsPsilocybin produced acute perceptual and subjective effects including, at 20 and/or 30 mg/70 kg, extreme anxiety/fear (39% of volunteers) and/or mystical-type experience (72% of volunteers). One month after sessions at the two highest doses, volunteers rated the psilocybin experience as having substantial personal and spiritual significance, and attributed to the experience sustained positive changes in attitudes, mood, and behavior, with the ascending dose sequence showing greater positive effects. At 14 months, ratings were undiminished and were consistent with changes rated by community observers. Both the acute and persisting effects of psilocybin were generally a monotonically increasing function of dose, with the lowest dose showing significant effects.ConclusionsUnder supportive conditions, 20 and 30 mg/70 kg psilocybin occasioned mystical-type experiences having persisting positive effects on attitudes, mood, and behavior. Implications for therapeutic trials are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High MEQ-30 scores have also been found to predict changes in personality-trait openness (MacLean et al., 2012) and positive changes in attitudes, mood, and behavior (Griffiths et al., 2011).”
From Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics (2024) · cites this paper as Griffiths et al., 2011
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“it has been repeatedly found that psychedelic-induced mystical-type experiences and ego dissolution, the latter a phenomenon characterized by the reduction in self-referential awareness, disruption self-world boundaries, and increased feelings of unity with one’s surroundings (55), correlates with long-term (positive) outcomes (23, 52–54, 56–58).”
From Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees (2022) · cites this paper as [57]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Compared to the active placebo group, both groups which received a high dose of psilocybin reported significantly higher enhancements in mood, well-being and life satisfaction, as assessed by the Persisting Effects Questionnaire (87).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [87]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“phase I and II studies suggest a dose-dependent effect on the quality of the psychedelic experience [54, 76]”
The cited source says what the claim attributes to it.
In the citing paper
“5 mg of psilocybin was shown to induce subjective changes significantly greater than those of an inert placebo; [76]”
The cited source says what the claim attributes to it.
In the citing paper
“with high mystical experience scores associated with 30 mg/70 kg of psilocybin [76]”
The cited source says what the claim attributes to it.
In the citing paper
“Undergoing a mystical-type experience during the acute effects of a psychedelic has been associated with healthy volunteers reporting an improvement in their wellbeing [51, 52], and reductions in depression symptoms in participants with life-threatening cancer [19, 20].”
From The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol (2022) · cites this paper as [51]
The cited source says what the claim attributes to it.
In the citing paper
“Mindfulness meditation and mindfulness-based interventions can augment positive affect in healthy and clinical populations acutely and long-term (10, 88) and a similar mood-enhancing potential has been demonstrated for psychedelics such as psilocybin (29, 38, 60, 83, 87).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [87]
The cited source says what the claim attributes to it.
In the citing paper
“Controlled studies where subjects achieved mystical experiences under the effects of psilocybin showed personal long-term benefits (Griffiths et al., 2008; Griffiths et al., 2011).”
From Psychological variables implied in the therapeutic effect of ayahuasca: A contextual approach (2018) · cites this paper as Griffiths et al., 2011
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Importantly, previous studies utilising psychedelic-administration outside of a mindfulness-enhancing context have failed to show such positive trait changes (83, 87, 133), with the exception of trait openness (74, 134).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [87]
Experimental — accuracy not yet measuredIn the citing paper
“and a dose-response study in healthy volunteers suggested that optimum psilocybin dosing for eliciting a well-tolerated yet transcendent experience may be between 0·29 mg/kg and 0·43 mg/kg [32].”
From Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study. (2020) · cites this paper as [32]
In the citing paper
“Self-reported increases in interpersonal closeness and positive/altruistic social effects were reported 1, 2, 6, and 14 months after one and two administrations of psilocybin (89–92).”
From Modulation of Social Cognition via Hallucinogens and “Entactogens” (2019) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 23×
“The questionnaire included three additional questions (see Griffiths et al. 2006 for more specific wording): (1) How personally meaningful was the experience?”
BackgroundMethodResultInfluentialSelf-citationThe Psychology of Religion: An Empirical Approach
Donahue, M. J., Hood, R. W., Spilka, B., Hunsberger, B. E., & Gorsuch, R. L. (1998) · Journal for the Scientific Study of Religion · doi:10.2307/1388044 · Cited by 1,339
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Self-citationMartin, W. R., Sloan, J. W., SAPIRA, J. D., & Jasinski, D. R. (1971) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1971122part1245 · Cited by 945
The Psychology of Religion: An Empirical Approach
Hall, C. M., Spilka, B., Hood, R. W., & Gorsuch, R. L. (1986) · Journal for the Scientific Study of Religion · doi:10.2307/1386305 · Cited by 943
Griffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905
Self-citationEvidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents
Glennon, R. A., Titeler, M., & MCKENNEY, J. D. J. (1984) · Life Sciences · doi:10.1016/0024-3205(84)90436-3 · Cited by 635
The Psychology of Religion: An Empirical Approach
Hunsberger, B. E., Spilka, B., Hood, R. W., & Gorsuch, R. L. (1986) · Review of Religious Research · doi:10.2307/3511875 · Cited by 626
Research works printed but not linked: 5
- Metzner R (2004) Teonanacatl: sacred mushroom of visions. Four Tree, El Verano
- Metzner R, Litwin G, Weil G (1965) The relation of expectation and mood to psilocybin reactions: a questionnaire study. Psychedelic Rev 5:3–39
- Pahnke W (1963) Drugs and mysticism: an analysis of the relationship between psychedelic drugs and the mystical consciousness. Thesis presented to the President and Fellows of Harvard University for the Ph.D. in Religion and Society
- Stolaroff MJ (1997) The secret chief revealed. Multidisciplinary Association for Psychedelic Studies, Sarasota
- VandeCreek L (1999) The death transcendence scale. In: Hill PC, Hood RW Jr (eds) Measures of religiosity. Religious Education Press, Birmingham, pp 442–445
Cited by
Sorted by citations
Items 101–200 of 979
Brouwer, A., & Carhart-Harris, R. L. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120959637 · Cited by 174
Sub-Acute Effects of Psilocybin on Empathy, Creative Thinking, and Subjective Well-Being
Mason, N. L., Mischler, E., Uthaug, M. V., & Kuypers, K. P. C. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1580804 · Cited by 172
Kettner, H., Gandy, S., Haijen, E. C. H. M., & Carhart-Harris, R. L. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16245147 · Cited by 171
Garcia‐Romeu, A., Davis, A. K., Erowid, E., Erowid, F., Griffiths, R. R., & Johnson, M. W. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00955 · Cited by 171
Self-citationDavis, A. K., Barrett, F. S., So, S., Gukasyan, N., Swift, T. C., & Griffiths, R. R. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120967878 · Cited by 169
Self-citationCameron, L. P., Benson, C. J., DeFelice, B. C., Fiehn, O., & Olson, D. E. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00692 · Cited by 168
Sloshower, J., Skosnik, P. D., Safi-Aghdam, H., Pathania, S., Syed, S., Pittman, B., & D’Souza, D. C. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231154852 · Cited by 165
Preparing for the bursting of the psychedelic hype bubble.
Yaden, D. B., Potash, J. B., & Griffiths, R. R. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.2546 · Cited by 162
Self-citationYao, Y., Guo, D., Lu, T., Liu, F.-L., Huang, S., Diao, M.-Q., Li, S., Zhang, X.-J., Kosten, T. R., Shi, J., et al. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115886 · Cited by 162
DARK Classics in Chemical Neuroscience: Psilocybin
Geiger, H. A., Wurst, M. G., & Daniels, R. N. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00186 · Cited by 159
Gukasyan, N., & Nayak, S. M. (2021) · Transcultural Psychiatry · doi:10.1177/1363461520983684 · Cited by 159
Sarris, J. J., McIntyre, E., & Camfield, D. (2013) · CNS Drugs · doi:10.1007/s40263-013-0059-9 · Cited by 157
Animal Models of Serotonergic Psychedelics
Hanks, J. B., & González-Maeso, J. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn300138m · Cited by 156
Psychedelic Drugs in Biomedicine
Kyzar, E. J., Nichols, C. D., Gainetdinov, R. R., Nichols, D. E., & Kalueff, A. V. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.08.003 · Cited by 155
Tripping on nothing: placebo psychedelics and contextual factors
Olson, J. A., Suissa-Rocheleau, L., Lifshitz, M., Raz, A., & Veissière, S. P. L. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05464-5 · Cited by 155
Madsen, M. K., Stenbæk, D. S., Arvidsson, A., Armand, S., Marstrand-Joergensen, M. R., Johansen, S. S., Línnet, K., Ozenne, B., Knudsen, G. M., & Fisher, P. M. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.06.001 · Cited by 155
Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse
Korpi, E. R., den Hollander, B., Farooq, U., Vashchinkina, E., Rajkumar, R., Nutt, D. J., Hyytiä, P., & Dawe, G. S. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010967 · Cited by 148
Davis, A. K., So, S., Lancelotta, R., Barsuglia, J. P., & Griffiths, R. R. (2019) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2018.1545024 · Cited by 142
Self-citationAn online survey of tobacco smoking cessation associated with naturalistic psychedelic use
Johnson, M. W., Garcia‐Romeu, A., Johnson, P. S., & Griffiths, R. R. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881116684335 · Cited by 140
Self-citationHistory repeating: guidelines to address common problems in psychedelic science
van Elk, M., & Fried, E. I. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231198466 · Cited by 137
Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects
MacLean, K. A., Johnson, M. W., Reissig, C. J., Prisinzano, T. E., & Griffiths, R. R. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2912-9 · Cited by 136
Self-citationDambrun, M. (2016) · Consciousness and Cognition · doi:10.1016/j.concog.2016.09.013 · Cited by 136
Timmermann, C., Watts, R., & Dupuis, D. (2022) · Transcultural Psychiatry · doi:10.1177/13634615221082796 · Cited by 136
Serotonergic psychedelics and personality: A systematic review of contemporary research
Bouso, J. C., dos Santos, R. G., Alcázar-Córcoles, M. Á., & Hallak, J. E. C. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.02.004 · Cited by 134
Making psychedelics into medicines: The politics and paradoxes of medicalization
Noorani, T. N. (2019) · Journal of Psychedelic Studies · doi:10.1556/2054.2019.018 · Cited by 134
Carbonaro, T. M., Johnson, M. W., Hurwitz, E., & Griffiths, R. R. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4769-4 · Cited by 133
Self-citationPsychedelic microdosing benefits and challenges: an empirical codebook
Anderson, T., Petranker, R., Christopher, A., Rosenbaum, D., Weissman, C. R., Dinh-Williams, L.-A., Hui, K., & Hapke, E. (2019) · Harm Reduction Journal · doi:10.1186/s12954-019-0308-4 · Cited by 133
Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers
Johnson, M. W., Sewell, R. A., & Griffiths, R. R. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.10.029 · Cited by 132
Self-citationAcute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects
Müller, F., Lenz, C., Dolder, P. C., Harder, S., Schmid, Y., Lang, U. E., Liechti, M. E., & Borgwardt, S. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.54 · Cited by 131
Ley, L., Holze, F., Arikci, D., Becker, A. M., Straumann, I., Klaiber, A., Coviello, F., Dierbach, S., Thomann, J., Duthaler, U., et al. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01607-2 · Cited by 130
Bogenschutz, M. P., & Pommy, J. M. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1376 · Cited by 130
Polito, V., & Liknaitzky, P. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104706 · Cited by 130
Synthesis and Structure–Activity Relationships of N -Benzyl Phenethylamines as 5-HT 2A/2C Agonists
Hansen, M. A., Phonekeo, K., Paine, J. S., Leth‐Petersen, S., Begtrup, M., Bräuner‐Osborne, H., & Kristensen, J. L. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn400216u · Cited by 129
Case analysis of long-term negative psychological responses to psychedelics
Bremler, R., Katati, N., Shergill, P., Erritzøe, D., & Carhart-Harris, R. L. (2023) · Scientific Reports · doi:10.1038/s41598-023-41145-x · Cited by 128
Treatment with psychedelics is psychotherapy: beyond reductionism
Gründer, G., Brand, M., Mertens, L. J., Jungaberle, H., Kärtner, L., Scharf, D., Spangemacher, M., & Wolff, M. (2023) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00363-2 · Cited by 126
Agin-Liebes, G., Haas, T. F., Lancelotta, R., Uthaug, M. V., Ramaekers, J. G., & Davis, A. K. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00018 · Cited by 124
Therapeutic use of psilocybin: Practical considerations for dosing and administration
MacCallum, C. A., Lo, L. A., Pistawka, C. A., & Deol, J. K. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1040217 · Cited by 122
Nielson, E. M., May, D. G., Forcehimes, A. A., & Bogenschutz, M. P. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00132 · Cited by 120
Subacute effects of the psychedelic ayahuasca on the salience and default mode networks
Pasquini, L., Palhano-Fontes, F., & de Araújo, D. B. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120909409 · Cited by 120
Classic Psychedelic Drugs: Update on Biological Mechanisms
Vollenweider, F. X., & Smallridge, J. W. (2022) · Pharmacopsychiatry · doi:10.1055/a-1721-2914 · Cited by 119
McCulloch, D. E.-W., Grzywacz, M. Z., Madsen, M. K., Jensen, P. S., Ozenne, B., Armand, S., Knudsen, G. M., Fisher, P. M., & Stenbæk, D. S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.841648 · Cited by 119
The Mechanisms of Psychedelic Visionary Experiences: Hypotheses from Evolutionary Psychology
Winkelman, M. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00539 · Cited by 116
LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation
Krähenmann, R., Pokorný, D., Aicher, H., Preller, K. H., Pokorny, T., Bosch, O. G., Seifritz, E., & Vollenweider, F. X. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00814 · Cited by 116
Erkizia-Santamaría, I., Alles-Pascual, R., Horrillo, I., Meana, J. J., & Ortega, J. E. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113612 · Cited by 114
Rucker, J., Marwood, L., Ajantaival, R.-L. J., Bird, C., Eriksson, H., Harrison, J., Lennard-Jones, M., Mistry, S. J., Saldarini, F., Stansfield, S. C., et al. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211064720 · Cited by 113
Psychedelic therapy in the treatment of addiction: the past, present and future
Zafar, R. R., Siegel, M., Harding, R., Barba, T., Agnorelli, C., Suseelan, S., Roseman, L., Wall, M. B., Nutt, D., & Erritzøe, D. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1183740 · Cited by 113
Horizontal gene cluster transfer increased hallucinogenic mushroom diversity
Reynolds, H. T., Vijayakumar, V., Gluck‐Thaler, E., Korotkin, H. B., Matheny, P. B., & Slot, J. C. (2018) · Evolution Letters · doi:10.1002/evl3.42 · Cited by 112
Kangaslampi, S. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00243 · Cited by 111
Psychedelic Microdosing: Prevalence and Subjective Effects
Cameron, L. P., Nazarian, A., & Olson, D. E. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1718250 · Cited by 110
Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey
Schindler, E. A. D., Gottschalk, C. H., Weil, M. J., Shapiro, R. E., Wright, D. A., & Sewell, R. A. (2015) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2015.1107664 · Cited by 110
McCulloch, D. E.-W., Knudsen, G. M., Barrett, F. S., Doss, M. K., Carhart-Harris, R. L., Rosas, F. E., Deco, G., Kringelbach, M. L., Preller, K. H., Ramaekers, J. G., et al. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104689 · Cited by 110
Barrett, F. S., Carbonaro, T. M., Hurwitz, E., Johnson, M. W., & Griffiths, R. R. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4981-x · Cited by 109
Self-citationNondual awareness: Consciousness-as-such as non-representational reflexivity
Josipovic, Z. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2018.10.021 · Cited by 109
Psychedelics and health behaviour change
Teixeira, P. J., Johnson, M. W., Timmermann, C., Watts, R., Erritzøe, D., Douglass, H. M., Kettner, H., & Carhart-Harris, R. L. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211008554 · Cited by 109
Self-citationClassical hallucinogens and neuroimaging: A systematic review of human studies
dos Santos, R. G., Osório, F. L., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.10.026 · Cited by 107
Riba, J., McIlhenny, E. H., Bouso, J. C., & Barker, S. A. (2014) · Drug Testing and Analysis · doi:10.1002/dta.1685 · Cited by 104
Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow
Lewis, C. R., Preller, K. H., Kraehenmann, R., Michels, L., Staempfli, P., & Vollenweider, F. X. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.07.020 · Cited by 102
Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress
Ross, S. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1482261 · Cited by 102
Williams, M. T., Davis, A. K., Xin, Y., Sepeda, N. D., Grigas, P. C., Sinnott, S., & Haeny, A. M. (2021) · Drugs: Education, Prevention and Policy · doi:10.1080/09687637.2020.1854688 · Cited by 101
Blough, B. E., Landavazo, A., Decker, A. M., Partilla, J. S., Baumann, M. H., & Rothman, R. B. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3557-7 · Cited by 101
Neuroticism is associated with challenging experiences with psilocybin mushrooms
Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2017) · Personality and Individual Differences · doi:10.1016/j.paid.2017.06.004 · Cited by 98
Self-citationPsychedelics and music: neuroscience and therapeutic implications
Barrett, F. S., Preller, K. H., & Kaelen, M. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1484342 · Cited by 98
Dose–response relationships of psilocybin-induced subjective experiences in humans
Hirschfeld, T., & Schmidt, T. T. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881121992676 · Cited by 97
Nayak, S. M., Jackson, H., Sepeda, N. D., Mathai, D. S., So, S., Yaffe, A., Zaki, H., Brasher, T. J., Lowe, M. X., Jolly, D. R. P., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1199642 · Cited by 97
Self-citationGarcia-Romeu, A., Barrett, F. S., Carbonaro, T. M., Johnson, M. W., & Griffiths, R. R. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881121991822 · Cited by 96
Self-citationDoes Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential?
Kočárová, R., Horáček, J., & Carhart-Harris, R. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.661233 · Cited by 96
Neural Mechanisms and Psychology of Psychedelic Ego Dissolution
Stoliker, D., Egan, G. F., Friston, K. J., & Razi, A. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000508 · Cited by 96
Belief changes associated with psychedelic use
Nayak, S. M., Singh, M., Yaden, D. B., & Griffiths, R. R. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221131989 · Cited by 96
Self-citationNunes, A. A., SANTOS, R. G. D., Osório, F. D. L., Sanches, R. F., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2016.1188225 · Cited by 95
Greenway, K. T., Garel, N., Jerome, L., & Feduccia, A. A. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1772054 · Cited by 94
The therapeutic potential of microdosing psychedelics in depression
Kuypers, K. P. C. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320950567 · Cited by 94
Mason, N. L., Szabó, A., Kuypers, K. P. C., Mallaroni, P., de la Torre, R., Reckweg, J. T., Tse, D. H. Y., Hutten, N. R. P. W., Feilding, A., & Ramaekers, J. G. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.09.004 · Cited by 94
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Zaretsky, T. G., Jagodnik, K. M., Barsic, R., Antonio, J. H., Bonanno, P. A., MacLeod, C., Pierce, C., Carney, H., Morrison, M. T., Saylor, C. F., et al. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666231027111147 · Cited by 92
Morgan, C. J. A., Noronha, L. A., Muetzelfeldt, M., Feilding, A., & Curran, H. V. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113477744 · Cited by 92
Leonard, J. B., Anderson, B. D., & Klein‐Schwartz, W. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118793086 · Cited by 91
High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens
Reissig, C. J., Carter, L. P., Johnson, M. W., Mintzer, M. Z., Klinedinst, M. A., & Griffiths, R. R. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2680-6 · Cited by 91
Self-citationTai, S. J., Nielson, E. M., Lennard-Jones, M., Johanna Ajantaival, R.-L., Winzer, R., Richards, W. A., Reinholdt, F., Richards, B. D., Gasser, P., & Malievskaia, E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.586682 · Cited by 90
Self-citationBarsuglia, J. P., Davis, A. K., Palmer, R. L., Lancelotta, R., Windham-Herman, A.-M., Peterson, K., Polanco, M., Grant, R., & Griffiths, R. R. (2018) · Frontiers in Psychology · doi:10.3389/fpsyg.2018.02459 · Cited by 90
Self-citationNeural and subjective effects of inhaled N,N-dimethyltryptamine in natural settings
Pallavicini, C., Cavanna, F., Zamberlán, F., de la Fuente, L. A., Ilksoy, Y. A., Perl, Y. S., Arias, M., Romero, C., Carhart-Harris, R. L., Timmermann, C., et al. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120981384 · Cited by 90
Bender, D., & Hellerstein, D. J. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06049-6 · Cited by 88
The induction of synaesthesia with chemical agents: a systematic review
Luke, D. P., & Terhune, D. B. (2013) · Frontiers in Psychology · doi:10.3389/fpsyg.2013.00753 · Cited by 88
High dose psilocybin is associated with positive subjective effects in healthy volunteers
Nicholas, C. R. N., Henriquez, K. M., Gassman, M., Cooper, K. M., Muller, D., Hetzel, S., Brown, R., Cozzi, N. V., Thomas, C., & Hutson, P. R. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118780713 · Cited by 87
Davis, A. K., Averill, L. A., Sepeda, N. D., Barsuglia, J. P., & Amoroso, T. (2020) · Chronic Stress · doi:10.1177/2470547020939564 · Cited by 87
Heuschkel, K., & Kuypers, K. P. C. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00224 · Cited by 86
Psychedelics, Sociality, and Human Evolution
Rodríguez Arce, J. M., & Winkelman, M. J. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.729425 · Cited by 86
Examining changes in personality following shamanic ceremonial use of ayahuasca
Weiss, B., Miller, J. D., Carter, N. T., & Keith Campbell, W. (2021) · Scientific Reports · doi:10.1038/s41598-021-84746-0 · Cited by 86
Kiraga, M. K., Mason, N. L., Uthaug, M. V., van Oorsouw, K. I. M., Toennes, S. W., Ramaekers, J. G., & Kuypers, K. P. C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.721537 · Cited by 85
Acute subjective effects in LSD- and MDMA-assisted psychotherapy
Schmid, Y., Gasser, P., Oehen, P., & Liechti, M. E. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959604 · Cited by 85
Moreton, S. G., Szalla, L., Menzies, R. E., & Arena, A. F. A. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05391-0 · Cited by 85
Handbook of Positive Psychology, Religion, and Spirituality
Davis, E. B., Worthington, E. L., & Schnitker, S. A. (2022) · Springer eBooks · doi:10.1007/978-3-031-10274-5 · Cited by 85
Lawn, W., Hallak, J. E. C., Crippa, J. A. S., SANTOS, R. G. D., Porffy, L., Barratt, M. J., Ferris, J., WINSTOCK, A. R., & Morgan, C. J. A. (2017) · Scientific Reports · doi:10.1038/s41598-017-14700-6 · Cited by 83
Replication and extension of a model predicting response to psilocybin
Russ, S. L., Carhart-Harris, R. L., Maruyama, G. M., & Elliott, M. S. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05279-z · Cited by 83
Stenbæk, D. S., Madsen, M. K., Ozenne, B., Kristiansen, S., Burmester, D., Erritzøe, D., Knudsen, G. M., & Fisher, P. M. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120959609 · Cited by 83
McCulloch, D. E.-W., Madsen, M. K., Stenbæk, D. S., Kristiansen, S., Ozenne, B., Jensen, P. S., Knudsen, G. M., & Fisher, P. M. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211026454 · Cited by 83
Raison, C. L., Jain, R., Penn, A., Cole, S. P., & Jain, S. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.831092 · Cited by 83
Psychedelics and Neural Plasticity: Therapeutic Implications
Grieco, S. F., Castrén, E., Knudsen, G. M., Kwan, A. C., Olson, D. E., Zuo, Y., Holmes, T. C., & Xu, X. (2022) · The Journal of Neuroscience · doi:10.1523/jneurosci.1121-22.2022 · Cited by 82
“…same level of 5-HT 2A R occupancy, which could clarify whether different psychedelics have comparable effects or whether their effects are distinct because of differences in efficacy, functional selectivity, or polypharma-cology (Griffiths et al., 2011; MacLean et al., 2011; Holze et al., 2022).”
Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample
Nygart, V. A., Pommerencke, L. M., Haijen, E. C. H. M., Kettner, H., Kaelen, M., Mortensen, E. L., Nutt, D. J., Carhart-Harris, R. L., & Erritzøe, D. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221101061 · Cited by 79
Psychedelics as an emerging novel intervention in the treatment of substance use disorder: a review
Divito, A. J., & Leger, R. F. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-06009-x · Cited by 78
Drug–drug interactions involving classic psychedelics: A systematic review
Halman, A., Kong, G., Sarris, J. J., & Perkins, D. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231211219 · Cited by 78
More Realistic Forecasting of Future Life Events After Psilocybin for Treatment-Resistant Depression
Lyons, T., & Carhart-Harris, R. L. (2018) · Frontiers in Psychology · doi:10.3389/fpsyg.2018.01721 · Cited by 77
Metadata
- Authors
- Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Griffiths, Roland R.
- Venue
- Psychopharmacology
- Published
- 2011-06-15
- Volume
- 218
- Issue
- 4
- Pages
- 649-665
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- PMC
- PMC3308357
- OpenAlex
- W2001101493
- Semantic Scholar
- b6a466d47ff14211f273622e5d0b584d06253237
- Cited by
- 932
- References
- 38
- Citations by year
- 2026: 59 · 2025: 97 · 2024: 115 · 2023: 110 · 2022: 107 · 2021: 94 · 2020: 64 · 2019: 65 · 2018: 48 · 2017: 51 · 2016: 40 · 2015: 18 · 2014: 23 · 2013: 18 · 2012: 14
- FWCI
- 20.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute on Drug Abuse (R01DA003889, R01DA03889)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Psychology › Social Psychology › Paranormal Experiences and Beliefs
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- psilocybin, dose-response relationship, fear and anxiety, long-term psychological effects, psychedelic therapy
- MeSH terms
- Adult, Affect, Attitude, Dose-Response Relationship, Drug, Double-Blind Method, Female, Follow-Up Studies, Hallucinogens, Humans, Male, Middle Aged, Psilocybin, Surveys and Questionnaires, Time Factors, Cross-Over Studies, Spirituality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
